Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Purdom

Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

Hematological Oncology

English

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Hematological Oncology

English

Related publications

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Journal of Clinical Oncology

English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology

English

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

Real-Life Use of Bendamustine for B-Cell Non-Hodgkin Lymphoma in a Community Hospital in Japan-Retreatment With Bendamustine Is Safe and Feasible

Hematological Oncology

English

Combination of Gemcitabine and Cisplatin Is Highly Active in Women With Endometrial Carcinoma

English

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Hematological Oncology

English

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

British Journal of Haematology

Hematology

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Purdom

Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Related publications

Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Real-Life Use of Bendamustine for B-Cell Non-Hodgkin Lymphoma in a Community Hospital in Japan-Retreatment With Bendamustine Is Safe and Feasible

Combination of Gemcitabine and Cisplatin Is Highly Active in Women With Endometrial Carcinoma

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study